Indaptus Therapeutics is trading 5.69% higher at $3.16 on October 23, 2026, with no identified company-specific catalyst for the intraday gain. - Recent coverage concerns the previously completed $24 million private placement, not a new event today. - Broader markets are mixed and the biotech sector is declining; available evidence does not establish a clear catalyst. - The price has rebounded from the October 22 close of $2.99, following a 5.38% decline that session.